Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients

J Antimicrob Chemother. 2015 May;70(5):1596-8. doi: 10.1093/jac/dku551. Epub 2015 Jan 14.
No abstract available

Keywords: ESBLs; P. aeruginosa; carbapenemases; extended-spectrum β-lactamases; β-lactamase inhibition.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Azabicyclo Compounds / pharmacology*
  • Ceftazidime / pharmacology*
  • Cystic Fibrosis / complications
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas Infections / microbiology
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / isolation & purification
  • beta-Lactam Resistance / drug effects*
  • beta-Lactamase Inhibitors / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • beta-Lactamase Inhibitors
  • avibactam
  • Ceftazidime